津药药业: 津药药业股份有限公司第九届董事会第二十次会议决议公告

Core Viewpoint - The board of directors of Tianyao Pharmaceutical Co., Ltd. held its 20th meeting of the 9th session on August 22, 2025, via telecommunication voting, and all resolutions were passed unanimously [1][2]. Group 1 - The meeting was attended by 9 directors, and all participated in the voting, which complied with the relevant provisions of the Company Law and the Articles of Association [1]. - The company agreed to the impairment provision plan based on actual circumstances, which aligns with the Accounting Standards for Enterprises and the company's financial management system [2]. - The audit and risk control committee of the board approved the impairment provision proposal, and the voting results showed 9 votes in favor, with no votes against or abstentions [2]. Group 2 - A risk assessment report was also presented, with non-related directors participating in the voting, resulting in 5 votes in favor and no votes against or abstentions [2]. - Related directors recused themselves from the voting process to ensure compliance with governance standards [2].